# An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still's Disease

> **NCT06497491** · PHASE3 · COMPLETED · sponsor: **AO GENERIUM** · enrollment: 118 (actual)

## Conditions studied

- Still's Disease Adult Onset

## Interventions

- **BIOLOGICAL:** GNR-086
- **BIOLOGICAL:** Ilaris®

## Key facts

- **NCT ID:** NCT06497491
- **Lead sponsor:** AO GENERIUM
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-12
- **Primary completion:** 2025-05-29
- **Final completion:** 2025-07-10
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2025-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06497491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06497491, "An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still's Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06497491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*